Ser212

Site Information
RrtAMrVsPHHPAPt SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4714837

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 10 , 11 , 13 , 15 , 16 , 17 , 18 , 19 )
Disease tissue studied:	breast cancer ( 6 ) , breast ductal carcinoma ( 6 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 6 ) , leukemia ( 13 , 15 ) , acute myelogenous leukemia ( 13 , 15 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 11 ) , acute megakaryoblastic leukemia (M7) ( 11 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 11 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 11 ) , acute myeloblastic leukemia, without maturation (M1) ( 11 ) , lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 4 ) , B cell lymphoma ( 11 ) , non-Hodgkin's lymphoma ( 11 ) , ovarian cancer ( 6 ) , multiple myeloma ( 11 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:	AML-193 (monocyte) ( 11 ) , breast ( 2 , 6 ) , CMK (megakaryoblast) ( 11 ) , CTS (myeloid) ( 11 ) , DOHH2 ('B lymphocyte, precursor') ( 11 ) , HEL (erythroid) ( 11 ) , HeLa (cervical) ( 5 , 10 ) , Jurkat (T lymphocyte) ( 8 , 16 , 17 , 18 , 19 ) , K562 (erythroid) ( 10 ) , Kasumi-1 (myeloid) ( 11 ) , KG-1 (myeloid) ( 11 , 15 ) , liver ( 7 ) , MV4-11 (macrophage) ( 11 , 13 ) , OPM-2 (plasma cell) ( 11 ) , ovary ( 6 ) , P31/FUJ (erythroid) ( 11 , 13 ) , PC9 (pulmonary) ( 4 ) , RL ('B lymphocyte, precursor') ( 11 ) , RPMI-8266 (plasma cell) ( 11 ) , SU-DHL-6 (B lymphocyte) ( 11 ) , U266 (plasma cell) ( 11 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 3 )

Upstream Regulation
Treatments:	selumetinib ( 3 ) , vemurafenib ( 3 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 32645325 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
4	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
5	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
6	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
7	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
8	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
9	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
10	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
11	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
12	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
13	Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66 22547687 Curated Info
14	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
15	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
16	Possemato A (2010) CST Curation Set: 10157; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
17	Possemato A (2010) CST Curation Set: 10141; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
18	Possemato A (2010) CST Curation Set: 10149; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
19	Possemato A (2010) CST Curation Set: 10147; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info